Patents by Inventor Malcolm NGIAM

Malcolm NGIAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A CYCLOSPORINE EMULSION AND PREPARATION METHOD THEREOF
    Publication number: 20260027052
    Abstract: The present invention relates to a cyclosporine emulsion and preparation method thereof, in particular to an oil-in-water cyclosporine emulsion, comprising an interfacial stabilizer, wherein the interfacial stabilizer comprises a combination of polyethylene glycol 15-hydroxystearate and a phospholipid. The emulsion has long-term stability in terms of the pH value, particle size and encapsulation rate.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 29, 2026
    Inventors: Shurong Zhang, Malcolm Ngiam, Qi Xue, Lu Niu, Zhenheng Wang, Yingluo Xiong, Peimin Dai, Yunzhe Wang
  • Recombinant human-basic fibroblast growth factor (rh-bFGF) and pharmaceutical composition comprising rh-bFGF
    Patent number: 11254723
    Abstract: Provided are a mutated nucleic acid molecule of a recombinant human-basic fibroblast growth factor (rh-bFGF), a pharmaceutical composition of the rh-bFGF, and a use thereof.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: February 22, 2022
    Assignee: Zhuhai Essex Bio-Pharmaceutical Co., Ltd.
    Inventors: Haizhou Fang, Peimin Dai, Bo Yang, Xinzhi Wang, Zhenheng Wang, Malcolm Ngiam, Qi Xue, Yingluo Xiong
  • Method for producing soluble recombinant human-basic fibroblast growth factor (rh-bFGF)
    Patent number: 11248032
    Abstract: Provided are a method for producing a soluble recombinant human-basic fibroblast growth factor (rh-bFGF), a recombinant human-basic fibroblast growth factor (rh-bFGF) obtained by the method, and a mutated nucleic acid molecule encoding the recombinant human-basic fibroblast growth factor (rh-bFGF).
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: February 15, 2022
    Assignee: ZHUHAI ESSEX BIO-PHARMACEUTICAL CO., LTD.
    Inventors: Haizhou Fang, Bo Yang, La Ma, Peimin Dai, Xinzhi Wang, Malcolm Ngiam, Qi Xue, Yongjun Yang
  • RECOMBINANT HUMAN-BASIC FIBROBLAST GROWTH FACTOR (rh-bFGF) AND PHARMACEUTICAL COMPOSITION COMPRISING rh-bFGF
    Publication number: 20200157164
    Abstract: Provided are a mutated nucleic acid molecule of a recombinant human-basic fibroblast growth factor (rh-bFGF), a pharmaceutical composition of the rh-bFGF, and a use thereof.
    Type: Application
    Filed: June 23, 2017
    Publication date: May 21, 2020
    Inventors: Haizhou FANG, Peimin DAI, Bo YANG, Xinzhi WANG, Zhenheng WANG, Malcolm NGIAM, Qi XUE, Yingluo XIONG
  • METHOD FOR PRODUCING SOLUBLE RECOMBINANT HUMAN-BASIC FIBROBLAST GROWTH FACTOR (rh-bFGF)
    Publication number: 20200140509
    Abstract: Provided are a method for producing a soluble recombinant human-basic fibroblast growth factor (rh-bFGF), a recombinant human-basic fibroblast growth factor (rh-bFGF) obtained by the method, and a mutated nucleic acid molecule encoding the recombinant human-basic fibroblast growth factor (rh-bFGF).
    Type: Application
    Filed: June 23, 2017
    Publication date: May 7, 2020
    Inventors: Haizhou FANG, Bo YANG, La MA, Peimin DAI, Xinzhi WANG, Malcolm NGIAM, Qi XUE, Yongjun YANG